Haemonetics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
125 Summer St, Boston, Massachusetts, 02...Phone Number
(781) 848-7100Website
www.haemonetics.comRevenue
$1.4 BillionStock Symbol
HAEIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
2
2
2
1
1
About Haemonetics
Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Our legacy of innovation was built on a dynamic approach to product development and customer support, an entrepreneurial-minded culture, and an unwavering commitment to quality, integrity and "making it matter" to patients around the world.Explore more
Haemonetics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Haemonetics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Haemonetics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Haemonetics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Haemonetics had a recent Job posting/layoffs
Haemonetics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Haemonetics is spiking on competitors!
Product Launch: Get notified when Haemonetics launches new products
Congratulate Masked Content for being promoted to Masked Content at Haemonetics
Funding: Get notified immidiatlly once Haemonetics has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Explore company insights
Get a deeper look into Haemonetics's structure, leadership, and market position:
Company Profile Activity
Activity Insights
Haemonetics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Haemonetics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Haemonetics.
Haemonetics financials insights
Gather financial insights about Haemonetics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Debt
$730M
Haemonetics Tech Stack
A closer look at the technologies used by Haemonetics
Most Recent Scoops
Hiring Plans
Haemonetics has more open roles in Finance than it has had at any time in the past 6 months. Areas of expertise include: Process Improvement, Tax Provision, Accounting, Auditing, General Ledger Reconciliation, Reporting and Analysis, and Use Tax.
Hiring Plans
Open Position
Person-Based
Earnings, Finance
Earnings
Haemonetics has reported that the FDA label expansion for MVP XL has opened the door for IDN contracting where the company previously had limited presence, with a 1,600-patient Emory University study supporting adoption in ambulatory surgery centers due to same-day discharge, rapid ambulation, minimal complications, and preserved access site benefits.
Medical Research, Clinical Operations
Earnings
Earnings, Accounting, Financial Reporting, Finance, Financial Operations
Haemonetics News & Media
5 Insightful Analyst Questions From Haemonetics’s Q2 Earnings Call
Haemonetics delivered a Q2 performance that surpassed Wall Street’s revenue and adjusted earnings expectations, supported by consistent execution across its business lines. Management attributed the quarter’s results to strong innovation and commercial momentum, particularly in Plasma and Interventional Technologies, where new product rollouts like Persona PLUS and VASCADE MVP XL drove adoption and utilization. CEO Christopher Simon specifically highlighted, "All three of our core platforms contHaemonetics Q1 Earnings Call Highlights
Haemonetics (NYSE:HAE) reported a stronger start to fiscal 2027, with first-quarter revenue rising 6% year over year to $339 million and adjusted diluted earnings per share increasing 4% to $1.14. The company raised its full-year revenue outlook, citing broad-based growth across its MedSurg and apheHaemonetics Corporation (HAE) Q1 2027 Earnings Call Transcript
Haemonetics Corporation (HAE) Q1 2027 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsOlga Guyette - VP of IR & TreasuryChristopher Simon -...Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON, Aug. 6, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2027, which ended June 27, 2026, are available on the Company's Investor Relations...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Haemonetics
Sign Up For FreeTo access detailed company insights
Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Ou... Read More
